Comparative Pharmacology
Head-to-head clinical analysis: CORGARD versus INDERAL LA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORGARD versus INDERAL LA.
CORGARD vs INDERAL LA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonselective beta-adrenergic receptor antagonist; competitively blocks beta1- and beta2-adrenergic receptors, leading to decreased heart rate, myocardial contractility, and blood pressure. Also prolongs sinoatrial node refractory period and inhibits renin release.
Propranolol is a non-selective beta-adrenergic receptor antagonist that competitively blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure; also inhibits renin release and reduces sympathetic outflow.
40 mg orally once daily for hypertension; initial dose 40 mg once daily for angina, titrate up to 80-240 mg once daily. Maximum dose 320 mg/day.
Initial: 80 mg orally once daily; titrate to 120-160 mg once daily; maximum 640 mg/day.
None Documented
None Documented
Terminal elimination half-life: 20-24 hours (may extend to 40 hours in renal impairment). Clinical context: Allows once-daily dosing; steady-state achieved in 5-7 days.
Terminal elimination half-life is 8-11 hours (range 4-16 hours) after oral administration. The extended-release formulation (INDERAL LA) results in a prolonged half-life of approximately 10 hours, allowing once-daily dosing.
Renal (unchanged, ~85-90%); fecal (<5%); biliary (<2%).
Primarily hepatic metabolism with renal elimination of metabolites. Less than 1% excreted unchanged in urine. Biliary/fecal excretion of metabolites accounts for approximately 20% of eliminated dose.
Category C
Category C
Beta-Blocker
Beta-Blocker